var data={"title":"Epoetin alfa: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Epoetin alfa: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6116?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=epoetin-alfa-drug-information\" class=\"drug drug_general\">see &quot;Epoetin alfa: Drug information&quot;</a> and <a href=\"topic.htm?path=epoetin-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Epoetin alfa: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708743\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Erythropoiesis-stimulating agents (ESAs) increase the risk of death, MI, stroke, venous thromboembolism, thrombosis of vascular access.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Chronic kidney disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a hemoglobin level of greater than 11 g/dL. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest epoetin alfa dose sufficient to reduce the need for RBC transfusions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cancer:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions. Use ESAs only for anemia from myelosuppressive chemotherapy. ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure. Discontinue following the completion of a chemotherapy course.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Perisurgery:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Due to increased risk of DVT, DVT prophylaxis is recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165764\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Epogen;</li>\n      <li>Procrit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165765\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Eprex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058391\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Colony-Stimulating Factor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Growth Factor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hematopoietic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Recombinant Human Erythropoietin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442420\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Anemia of prematurity:</b> Limited data available; dosing regimens and efficacy results variable: <b>Note:</b> Role in therapy not determined; some experts recommend to avoid use due to increased risk of adverse effects (eg, retinopathy of prematurity) (Aher 2014; Ohlsson 2014): IV, SubQ: Reported range: 150 to 1,500 units/kg/<b>week</b> divided into 2 to 5 doses (Alarcon 2005); a commonly accepted regimen is 250 units/kg/dose 3 times weekly for 10 doses; supplement with oral iron therapy (Kenner 2007; Maier 1994); a small trial used a weekly dose of 1,200 units/kg once weekly and reported increased reticulocytes and maintained hematocrit similar to 3 times a week dosing in 10 neonates (GA: 27.9 &plusmn; 0.6 weeks; birth weight: 922 &plusmn; 75 g) (Ohls 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Neuroprotective/hypoxic ischemia encephalopathy (HIE):</b> Limited data available, dosing regimens variable:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Low dose: Initial dose: SubQ: 300 or 500 units/kg/dose; maintenance dose: IV: 300 or 500 units/kg/dose every other day for 2 weeks beginning within first 48 hours of life was used in 73 neonates diagnosed with moderate HIE; improved neurologic outcomes were reported at 18 months of age (Zhu 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">High dose: IV, SubQ: 1,000 or 2,500 units/kg/dose once daily for 3 to 5 days beginning within first 24 hours of life; dosing based on a Phase I/II safety and pharmacokinetic, case-control study of 30 ELBW neonates (mean GA: 26.1 weeks, birth weight: 745 g) which showed dosing &ge;1,000 units/kg IV provided proposed target serum concentration for neuroprotective effects (&gt;6,000 mIU/mL) and reported a diminished severity of ICH in treatment groups (Juul, 2008). In a prospective, case-controlled pilot efficacy trial, 15 term neonates diagnosed with HIE received SubQ administration of 2,500 units/kg/dose for 5 days beginning within first 24 hours of life; short-term findings (PNA: 2 weeks) included decreased nitric oxide serum concentrations and fewer seizures; long-term finding (PNA: 6 months) included fewer neurologic abnormalities (Elmahdy 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058385\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=epoetin-alfa-drug-information\" class=\"drug drug_general\">see &quot;Epoetin alfa: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">Dosing schedules need to be individualized and careful monitoring of patients receiving the drug is recommended. Use has not been demonstrated in controlled clinical trials to improve symptoms of anemia, quality of life, fatigue, or patient well-being. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia in chronic kidney disease (ON dialysis):</b> <b>Note:</b> IV route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants, Children, and Adolescents &le;16 years: IV, SubQ: 50 units/kg/dose 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &gt;16 years: 50 to 100 units/kg 3 times/week </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustments:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin does <b>not</b> increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by &ge;25%; dose reductions can occur more frequently than once every 4 weeks; avoid frequent dosage adjustments</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain an Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia in chronic kidney disease (NOT on dialysis):</b> Adolescents &gt;16 years: <b>Note:</b> Consider initiating treatment when \themoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 10 g/dL: IV, SubQ: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 50 to 100 units/kg 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustments:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin does <b>not</b> increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by &ge;25%; dose reductions can occur more frequently than once every 4 weeks; avoid frequent dosage adjustments</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain a Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia due to myelosuppressive chemotherapy (palliative) in cancer patients:</b> <b>Note:</b> Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is &ge;2 months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Children &ge;5 years and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial dose: 600 units/kg/dose once weekly until completion of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustments:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin does not increase by &gt;1 g/dL <b>and</b> remains &lt;10 g/dL after initial 4 weeks: Increase to 900 units/kg/dose (maximum dose: 60,000 units/dose); discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin exceeds a level needed to avoid red blood cell transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period <b>or</b> hemoglobin reaches a level sufficient to avoid red blood cell transfusion: Reduce dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia due to zidovudine in HIV-infected patients:</b> Limited data available: <b>Note:</b> Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Infants &ge;3 months, Children, and Adolescents &le;17 years: IV, SubQ: Doses ranging from 50 to 400 units/kg/dose 2 to 3 times weekly have been reported; withhold dose if hemoglobin exceeds 12 g/dL, may resume treatment with a 25% dose reduction once hemoglobin &lt;11 g/dL (Ferri, 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia associated with chronic kidney disease:</b> Individualize dosing and use the lowest dose necessary to reduce the need for RBC transfusions.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic kidney disease patients <b>ON dialysis</b> (IV route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 11 g/dL): IV, SubQ: Initial dose: 50 to 100 units/kg/dose 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic kidney disease patients <b>NOT on dialysis</b> (consider initiating treatment when hemoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 10 g/dL): IV, SubQ: Initial dose: 50 to 100 units/kg/dose 3 times/week</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustments for chronic kidney disease patients (either on dialysis or not on dialysis):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%; do not increase the dose more frequently than once every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Reduce dose by &ge;25%; dose reductions can occur more frequently than once every 4 weeks; avoid frequent dosage adjustments</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Inadequate or lack of response over a 12-week escalation period: Further increases are unlikely to improve response and may increase risks; use the minimum effective dose that will maintain an Hgb level sufficient to avoid RBC transfusions and evaluate patient for other causes of anemia. Discontinue therapy if responsiveness does not improve.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia due to chemotherapy in cancer patients:</b> Initiate treatment only if hemoglobin &lt;10 g/dL and anticipated duration of myelosuppressive chemotherapy is &ge;2 months. Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Discontinue erythropoietin following completion of chemotherapy. SubQ: Initial dose: 150 units/kg/dose 3 times weekly or 40,000 units once weekly until completion of chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosage adjustments:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin does not increase by &gt;1 g/dL <b>and</b> remains below 10 g/dL after initial 4 weeks: Increase to 300 units/kg/dose 3 times weekly or 60,000 units weekly; discontinue after 8 weeks of treatment if RBC transfusions are still required or there is no hemoglobin response</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin exceeds a level needed to avoid red blood cell transfusion: Withhold dose; resume treatment with a 25% dose reduction when hemoglobin approaches a level where transfusions may be required</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period <b>or</b> hemoglobin reaches a level sufficient to avoid red blood cell transfusion: Reduce dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia due to zidovudine in HIV-infected patients:</b> Titrate dosage to use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions. Hemoglobin levels should not exceed 12 g/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum erythropoietin levels &le;500 mUnits/mL and zidovudine doses &le;4200 mg/week): IV, SubQ: Initial: 100 units/kg/dose 3 times weekly; if hemoglobin does not increase after 8 weeks, increase dose by ~50 to 100 units/kg/dose at 4 to 8 week intervals until hemoglobin reaches a level sufficient to avoid RBC transfusion; maximum dose: 300 units/kg/dose. Withhold dose if hemoglobin exceeds 12 g/dL, may resume treatment with a 25% dose reduction once hemoglobin &lt;11 g/dL. Discontinue if hemoglobin increase is not achieved with 300 units/kg/dose for 8 weeks. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Surgery patients</b> (perioperative hemoglobin should be &gt;10 g/dL and &le;13 g/dL; DVT prophylactic anticoagulation is recommended): SubQ: Initial dose:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">300 units/kg/day beginning 10 days before surgery, on the day of surgery, and for 4 days after surgery <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">600 units/kg once weekly for 4 doses, given 21 , 14, and 7 days before surgery, and on the day of surgery</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b> Infants, Children, Adolescents, and Adults: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165738\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epogen: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procrit: 10,000 units/mL (2 mL); 20,000 units/mL (1 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epogen: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Procrit: 2000 units/mL (1 mL); 3000 units/mL (1 mL); 4000 units/mL (1 mL); 10,000 units/mL (1 mL); 40,000 units/mL (1 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165724\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874643\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Epogen: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5360s5364lbl.pdf#page=58&amp;token=xFJ8BddpD9cyB11fv7QUlWXUSNSYKMnKJnuMCtUf+QkJG8ObiqeL7DMssLDULzlhmzwfQWgsN0pk+QPtbXlyw94yWINU3vy6Zu17MVL7JtKksDlIc53V5oFg97jd6zIL&amp;TOPIC_ID=13273\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5360s5364lbl.pdf#page=58</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Procrit: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM088988.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn//6Xg8g/NxRlbr2OO28Pv6+fgoiCvLQLc6nlvKfQK+AZw==&amp;TOPIC_ID=13273\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM088988.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058395\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Do not shake as this may denature the glycoprotein rendering the drug biologically inactive; do not use if product has been shaken or frozen.   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">SubQ: Preferred  route of administration except in patients with CKD on hemodialysis; 1:1 dilution with bacteriostatic NS (containing benzyl alcohol) acts as a local anesthetic to reduce pain at the injection site. Multiple-dose vials already contain benzyl alcohol. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Manufacturer recommends administering without dilution; some institutions may further dilute with NS; infuse over 1 to 3 minutes; it may be administered into the venous line at the end of the dialysis procedure. In neonates, may be infused over 4 hours when diluted in parenteral nutrition or dextrose containing IVF with at least 0.05% protein (amino acids or albumin) (Ohls 1996; Ohls 1997)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165758\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Vials should be stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). <b>Do not freeze. Do not shake</b>. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Single-dose 1 mL vial</b> contains no preservative. Use one dose per vial. Do not re-enter vial; discard unused portions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Single-dose vials (except 40,000 units/mL vial) are stable for 2 weeks at room temperature (Cohen 2007). Single-dose 40,000 units/mL vial is stable for 1 week at room temperature.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Multidose 1 mL or 2 mL vial</b> contains preservative. Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) after initial entry and between doses. Discard 21 days after initial entry.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Multidose vials (with preservative) are stable for 1 week at room temperature (Cohen 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prefilled syringes containing the 20,000 units/mL formulation with preservative are stable for 6 weeks refrigerated (2&deg;C to 8&deg;C) (Naughton 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dilutions of 1:10 and 1:20 (1 part epoetin alfa:19 parts sodium chloride) are stable for 18 hours at room temperature (Ohls 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prior to SubQ administration, preservative free solutions may be mixed with bacteriostatic NS containing benzyl alcohol 0.9% in a 1:1 ratio (Corbo 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dilutions of 1:10 in D10W with human albumin 0.05% or 0.1% are stable for 24 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058394\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of anemia associated with chronic kidney disease (CKD) in patients on dialysis (FDA approved in ages 1 month to 16 years and adults); treatment of anemia associated with CKD without dialysis (FDA approved in adults); anemia in cancer patients with nonmyeloid malignancies receiving concurrent myelosuppressive chemotherapy (palliative intent) when chemotherapy is a planned for a minimum of 2 months (FDA approved in ages &ge;5 years and adults); anemia related to HIV therapy with zidovudine (FDA approved in adults); reduction of allogeneic RBC transfusion for elective, noncardiac, nonvascular surgery when perioperative hemoglobin is &gt;10 to &le;13 g/dL and with high risk for blood loss (FDA approved in adults); has also been used for anemia of prematurity; treatment of symptomatic anemia in myelodysplastic syndrome </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165818\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epoetin alfa may be confused with darbepoetin alfa, methoxy polyethylene glycol-epoetin beta </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Epogen may be confused with Neupogen</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Epopen [Spain] may be confused with EpiPen brand name for epinephrine [US, Canada, and multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165814\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Deep vein thrombosis, edema, hypertension, thrombosis, thrombosis of hemodialysis vascular access</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, depression, dizziness, headache, insomnia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, hypokalemia, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dysphagia, nausea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site pain, irritation at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, muscle spasm, myalgia, ostealgia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Antibody development (neutralizing), cardiac failure, cerebrovascular accident, erythema, erythema multiforme, hypertensive encephalopathy, myocardial infarction, porphyria, pure red cell aplasia, seizure, severe anemia, skin blisters, skin exfoliation, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165745\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious allergic reactions to epoetin alfa or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (PRCA) that begins after treatment with epoetin alfa or other epoetin protein drugs; multidose vials contain benzyl alcohol and are contraindicated in neonates, infants, pregnant women, and breastfeeding women</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling</i>: Additional contraindications (not in US labeling): Known hypersensitivity to mammalian cell-derived products or any component of the formulation; patients who for any reason cannot receive adequate antithrombotic treatment; use in patients with severe coronary, peripheral arterial, carotid, or cerebral vascular disease, including patients with recent MI or cerebral vascular accident scheduled for elective surgery and not participating in an autologous blood donation program.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165728\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: <b>[US Boxed Warning]: Erythropoiesis-stimulating agents (ESAs) increased the risk of serious cardiovascular events, MI, stroke, venous thromboembolism, vascular access thrombosis, and mortality in clinical studies when administered to target hemoglobin levels &gt;11 g/dL</b> (and provide no additional benefit); a rapid rise in hemoglobin (&gt;1 g/dL over 2 weeks) may also contribute to these risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous reactions: Erythema multiforme and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) have been reported with ESA use; discontinue immediately if a severe cutaneous reaction develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Potentially serious allergic reactions have been reported (rarely), including anaphylactic reactions, angioedema, bronchospasm, rash, and urticaria. Discontinue immediately (and permanently) in patients who experience serious allergic/anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pure red cell aplasia (PRCA): Cases of severe anemia and PRCA have been reported, predominantly in patients with chronic kidney disease receiving SubQ epoetin alfa (the IV route is preferred for hemodialysis patients); cases have also been reported in patients with hepatitis C who were receiving ESAs, interferon, and ribavirin. Patients with a sudden loss of response (with severe anemia and a low reticulocyte count) should be evaluated for PRCA with associated neutralizing antibodies to erythropoietin; discontinue treatment (permanently) in patients with PRCA secondary to neutralizing antibodies to erythropoietin. Antibodies may cross-react; do not switch to another ESA in patients who develop antibody-mediated anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cancer patients: <b>[US Boxed Warning]: A shortened overall survival and/or increased risk of tumor progression or recurrence has been reported in studies with breast, cervical, head and neck, lymphoid, and non-small cell lung cancer patients.</b> It is of note that in most of in these studies, patients received ESAs to a target hemoglobin of &ge;12 g/dL; although risk has not been excluded when dosed to achieve a target hemoglobin of &lt;12 g/dL. <b>[US Boxed Warnings]: To decrease these risks, and risk of cardio and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions. Use ESAs in cancer patients only for the treatment of anemia related to concurrent myelosuppressive chemotherapy; discontinue ESA following completion of the chemotherapy course. ESAs are <span style=\"text-decoration: underline\">not</span> indicated for patients receiving myelosuppressive therapy when the anticipated outcome is curative.</b> A dosage modification is appropriate if hemoglobin levels rise &gt;1 g/dL per 2-week time period during treatment (ASCO/ASH [Rizzo 2010]). Use of ESAs has been associated with an increased risk of VTE without a reduction in transfusions in patients &gt;65 years of age with cancer (Hershman 2009). Improved anemia symptoms, quality of life, fatigue, or well-being have not been demonstrated in controlled clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic kidney disease patients: <b>[US Boxed Warning]: An increased risk of death, serious cardiovascular events, and stroke was reported in chronic kidney disease (CKD) patients administered ESAs to target hemoglobin levels &gt;11 g/dL; use the lowest dose sufficient to reduce the need for RBC transfusions. An optimal target hemoglobin level, dose or dosing strategy to reduce these risks has not been identified in clinical trials.</b> Hemoglobin rising &gt;1 g/dL in a 2-week period may contribute to the risk (dosage reduction recommended). CKD patients who exhibit an inadequate hemoglobin response to ESA therapy may be at a higher risk for cardiovascular events and mortality compared to other patients. ESA therapy may reduce dialysis efficacy (due to increase in red blood cells and decrease in plasma volume); adjustments in dialysis parameters may be needed. Patients treated with epoetin alfa may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Use with caution in patients with a history of hypertension (contraindicated in uncontrolled hypertension). An excessive rate of rise of hemoglobin is associated with hypertension or exacerbation of hypertension; decrease the epoetin alfa dose if the hemoglobin increase exceeds 1 g/dL in any 2-week period. Blood pressure should be controlled prior to start of therapy and monitored closely throughout treatment. Hypertensive encephalopathy has been reported with patients receiving erythropoietic therapy; monitor closely and control blood pressure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Perisurgery patients: <b>[US Boxed Warning]: DVT prophylaxis is recommended in perisurgery patients due to the increased risk of DVT. </b> Increased mortality was also observed in patients undergoing coronary artery bypass surgery who received epoetin alfa; these deaths were associated with thrombotic events. Epoetin alfa is <b>not</b> approved for reduction of red blood cell transfusion in patients undergoing cardiac or vascular surgery and is <b>not</b> indicated for surgical patients willing to donate autologous blood.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: The risk for seizures is increased with epoetin alfa use in patients with CKD; use with caution in patients with a history of seizures. Monitor closely for neurologic symptoms during the first several months of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Severe anemia or acute blood loss: Due to the delayed onset of erythropoiesis, epoetin alfa is not recommended for acute correction of severe anemia or as a substitute for emergency transfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage form specific issues:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Product may contain albumin, which confers a theoretical risk of transmission of viral disease or Creutzfeldt-Jakob disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Oncology: The American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) 2010 updates to the clinical practice guidelines for the use of ESAs in patients with cancer indicate that ESAs are appropriate when used according to the parameters identified within the FDA approved labeling for epoetin and darbepoetin alfa (ASCO/ASH [Rizzo 2010]). ESAs are an option for chemotherapy associated anemia when the hemoglobin has fallen to &lt;10 g/dL to decrease the need for RBC transfusions. ESAs should only be used in conjunction with concurrent chemotherapy. Although the FDA label now limits ESA use to the palliative setting, the ASCO/ASH guidelines suggest using clinical judgment in weighing risks versus benefits as formal outcomes studies of ESA use defined by intent of chemotherapy treatment have not been conducted.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Cardiovascular disease: The American College of Physicians recommends against the use of ESAs in patients with mild to moderate anemia and heart failure or coronary heart disease (ACP [Qaseem 2013]). The ACCF/AHA 2013 Heart Failure Guidelines do not provide a clear recommendation on the use of ESAs in anemic heart failure patients. The effects of ESAs on quality of life measures, morbidity, and mortality are potentially modest and still unclear. Additionally, the safety of epoetin alfa has not been well studied in this population. The authors declined to provide an official recommendation regarding the use of ESAs pending the completion of ongoing randomized trials (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Factors impairing erythropoiesis: Prior to treatment, correct or exclude deficiencies of iron, vitamin B<sub>12</sub>, and/or folate, as well as other factors which may impair erythropoiesis (inflammatory conditions, infections, bleeding). Poor response to therapy should prompt evaluation of potential factors impairing erythropoiesis, as well as possible malignant processes and hematologic disease (thalassemia, refractory anemia, myelodysplastic disorder), occult blood loss, hemolysis, osteitis fibrosa cystic, and/or bone marrow fibrosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26715203\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May be associated with an increased risk of retinopathy of prematurity (ROP); an increase in ROP has been observed in neonates receiving epoetin alfa for anemia of prematurity, with a reported incidence of 15% to 17%; however, a direct association with the drug has not been established. A meta-analysis of early treatment with epoetin alfa showed that neonates treated within the first week of life did not have a significant increased incidence in stage &ge;3 ROP; however, a post-ad hoc data analysis of all neonates (regardless of age at treatment) showed an increased risk (Ohlsson 2014); a meta-analysis of late treatment showed an overall trend toward increased incidence of ROP (all stages) and at stage &ge; 3 (Aher 2014).  Risks and benefits should be assessed prior to initiation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299274\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220130\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13273&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nandrolone: May enhance the stimulatory effect of Erythropoiesis-Stimulating Agents. Specifically, nandrolone may enhance the erythropoiesis stimulatory effect of Erythropoiesis-Stimulating Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165734\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165749\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. In vitro studies suggest that recombinant erythropoietin does not cross the human placenta (Reisenberger 1997). Polyhydramnios and intrauterine growth retardation have been reported with use in women with chronic kidney disease (adverse effects also associated with maternal disease). Hypospadias and pectus excavatum have been reported with first trimester exposure (case report).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Recombinant erythropoietin alfa has been evaluated as adjunctive treatment for severe pregnancy associated iron deficiency anemia (Breymann 2001; Krafft 2009) and has been used in pregnant women with iron-deficiency anemia associated with chronic kidney disease (CKD) (Furaz-Czerpak 2012; Josephson 2007).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Amenorrheic premenopausal women should be cautioned that menstruation may resume following treatment with recombinant erythropoietin (Furaz-Czerpak 2012). Multidose formulations containing benzyl alcohol are contraindicated for use in pregnant women; if treatment during pregnancy is needed, single dose preparations should be used.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Women who become pregnant during treatment with epoetin alfa are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (1-800-772-6436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058390\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Transferrin saturation and serum ferritin (prior to and during treatment); hemoglobin (weekly after initiation and following dose adjustments until stable and sufficient to minimize need for RBC transfusion, CKD patients should be also be monitored at least monthly following hemoglobin stability); blood pressure; seizures (CKD patients following initiation for first few months, includes new-onset or change in seizure frequency or premonitory symptoms)</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Cancer patients: Examinations recommended by the ASCO/ASH guidelines (Rizzo, 2010) prior to treatment include: Peripheral blood smear (in some situations a bone marrow exam may be necessary), assessment for iron, folate, or vitamin B<sub>12</sub> deficiency, reticulocyte count, renal function status, and occult blood loss; during ESA treatment, assess baseline and periodic iron, total iron-binding capacity, and transferrin saturation or ferritin levels</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058393\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Adult zidovudine-treated HIV patients: Available evidence indicates patients with endogenous serum erythropoietin concentrations &gt;500 mIU/mL are unlikely to respond </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165727\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Epoetin alfa induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose response relationship with this effect. This results in an increase in reticulocyte counts followed by a rise in hematocrit and hemoglobin levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165744\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> While a much higher peak plasma concentration is achieved after IV bolus administration, it declines at a more rapid rate than after subcutaneous administration (McMahon 1990; Salmonson 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Reticulocyte count increase: Within 10 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: Hemoglobin level: 2 to 6 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: SubQ: Slow (McMahon 1990; Salmonson 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 9 L; rapid in the plasma compartment; concentrated in liver, kidneys, and bone marrow; similar to extracellular plasma volume in adults (McMahon 1990; Salmonson 1990); reported to be higher in premature neonates on body weight basis (Brown 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Some degradation does occur</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: SubQ: Premature neonates: 42% (Brown 1993); Adults: 36% (Salmonson 1990); intraperitoneal epoetin alfa: 3% (Macdougall 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neonates: With high doses, nonlinear kinetics have been observed (Wu 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Anemia of prematurity:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Post menstrual age (PMA) &lt;32 week (weight: 800 &plusmn; 206 grams): IV: 8.1 &plusmn; 2.7 hours; SubQ: 7.1 &plusmn; 4.1 hours (Brown 1993)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">PMA &ge;32 weeks (weight range: 1,330 to 1,740 g): SubQ: Median: 7.9 hours (range: 5.6 to 19.4 hours) (Krishnan 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neuroprotective/hypoxic ischemia encephalopathy (HIE) (Wu 2012): &ge;36 weeks GA; IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">250 units/kg: 7.6 &plusmn; 6.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">500 units/kg: 7.2 &plusmn; 1.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">1,000 units/kg: 15 &plusmn; 4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2,500 units/kg: 18.7 &plusmn; 4.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Chronic kidney disease: IV: 4 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Cancer: SubQ: 16 to 67 hours; Chronic kidney disease: IV: 4 to 13 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Pediatric patients &gt;1 month and Adults: Chronic kidney disease: SubQ: 5 to 24 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165748\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Epogen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 units/mL (1 mL): $39.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 units/mL (1 mL): $59.69</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 units/mL (1 mL): $79.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 units/mL (1 mL): $198.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000 units/mL (1 mL): $397.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Procrit Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 units/mL (1 mL): $61.74</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 units/mL (1 mL): $92.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4000 units/mL (1 mL): $123.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10000 units/mL (1 mL): $308.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20000 units/mL (1 mL): $617.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40000 units/mL (1 mL): $1,234.63</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F165751\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abseamed (TR);</li>\n      <li>Binocrit (CH, ES, GB, HR, IE, IL, JO, MT, MY, RO, TR);</li>\n      <li>Efotin (PH);</li>\n      <li>EPIAO (TH);</li>\n      <li>Epodion (ID);</li>\n      <li>Epogen (PH);</li>\n      <li>Epokine (PH);</li>\n      <li>Eporon (TH);</li>\n      <li>Eposino (PH);</li>\n      <li>Eposis (KR, PH, TH);</li>\n      <li>Epotin (AE, KW, LB, QA);</li>\n      <li>Epovax (PH);</li>\n      <li>Eprex (AE, AR, AU, BB, BD, BE, BG, BH, BM, BR, BS, BZ, CH, CR, CY, CZ, DK, DO, EE, EG, ES, FI, FR, GB, GR, GT, GY, HK, HN, HR, HU, IE, IN, IQ, IR, IT, JM, JO, KW, LB, LK, LU, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PY, QA, RO, RU, SA, SE, SG, SR, SV, SY, TH, TR, TT, TW, UY, VE, VN, YE);</li>\n      <li>Erykine (TZ);</li>\n      <li>Erypo (AT, DE);</li>\n      <li>Espo (CN, JP);</li>\n      <li>Espogen (TH);</li>\n      <li>Hemapo (TH, VN);</li>\n      <li>Hemax (TH);</li>\n      <li>Hypercrit (BR, CL);</li>\n      <li>Renogen (PH, TH);</li>\n      <li>Repoitin 4000 (PH);</li>\n      <li>Yi Pu Li (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aher SM, Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.<i> Cochrane Database Syst Rev</i>. 2014;4:CD004868.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/24760628 /pubmed\" target=\"_blank\" id=\"24760628 \">24760628 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Breymann C, Visca E, Huch R, et al, &quot;Efficacy and Safety of Intravenously Administered Iron Sucrose With and Without Adjuvant Recombinant Human Erythropoietin for the Treatment of Resistant Iron-Deficiency Anemia During Pregnancy,&quot; <i>Am J Obstet Gynecol</i>, 2001, 184(4):662-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/11262469/pubmed\" target=\"_blank\" id=\"11262469\">11262469</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brown MS, Eichorst D, Lala-Black B, et al, &quot;Higher Cumulative Doses of Erythropoietin and Developmental Outcomes in Preterm Infants,&quot; <i>Pediatrics</i>, 2009, 124(4):681-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/19786428/pubmed\" target=\"_blank\" id=\"19786428\">19786428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health-Syst Pharm</i>. 2007;64(16):1711-1715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Corbo DC, Suddith RL, Sharma B, et al. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent. <i>Am J Hosp Pharm</i>. 1992;49(6):1455-1458.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/1529989/pubmed\" target=\"_blank\" id=\"1529989\">1529989</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Elmahdy H, El-Mashad AR, El-Bahrawy H, et al, &quot;Human Recombinant Erythropoietin in Asphyxia Neonatorum: Pilot Trial,&quot; <i>Pediatrics</i>, 2010, 125(5):1135-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/20385632/pubmed\" target=\"_blank\" id=\"20385632\">20385632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferri RS, Adinolfi A, Orsi AJ, et al. Treatment of anemia in patients with HIV infection--part 2: guidelines for management of anemia. <i>J Assoc Nurses AIDS Care</i>. 2002;13(1):50-59. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/11828859 /pubmed\" target=\"_blank\" id=\"11828859 \">11828859 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furaz-Czerpak KR, Fern&aacute;ndez-Ju&aacute;rez G, Moreno-de la Higuera M&Aacute;, et al, &quot;Pregnancy in Women on Chronic Dialysis: A Review,&quot; <i>Nefrologia</i>, 2012, 32(3):287-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/22508145/pubmed\" target=\"_blank\" id=\"22508145\">22508145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Halperin DS, Wacker P, Lacourt G, et al, &ldquo;Effects of Recombinant Human Erythropoietin in Infants With the Anemia of Prematurity: A Pilot Study,&rdquo; <i>J Pediatr</i>, 1990, 116(5):779-86. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/ 1691780 /pubmed\" target=\"_blank\" id=\" 1691780 \"> 1691780 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershman DL, Buono DL, Malin J, et al, &ldquo;Patterns of Use and Risks Associated With Erythropoiesis-Stimulating Agents Among Medicare Patients With Cancer,&rdquo; <i>J Natl Cancer Inst</i>, 2009, 101(23):1-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/19903808/pubmed\" target=\"_blank\" id=\"19903808\">19903808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n     Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Josephson MA and McKay DB, &quot;Considerations in the Medical Management of Pregnancy in Transplant Recipients, <i>Adv Chronic Kidney Dis</i>, 2007, 14(2):156-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/17395118/pubmed\" target=\"_blank\" id=\"17395118\">17395118</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juul SE, McPherson RJ, Bauer LA, et al, &quot;A Phase I/II Trial of High-Dose Erythropoietin in Extremely Low Birth Weight Infants: Pharmacokinetics and Safety,&quot; <i>Pediatrics</i>, 2008, 122(2):383-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/18676557/pubmed\" target=\"_blank\" id=\"18676557\">18676557</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    KDOQI, &quot;KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target,&quot; <i>Am J Kidney Dis</i>, 2007, 50(3):471-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/17720528/pubmed\" target=\"_blank\" id=\"17720528\">17720528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kenner, C, Wright Litt, J, eds. <i>Comprehensive Noenatal Care: An Interdisciplainary Approach</i>. Elsevier Health Sciences; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krafft A, Bencaiova G, and Breymann C, &quot;Selective Use of Recombinant Human Erythropoietin in Pregnant Patients With Severe Anemia or Nonresponsive to Iron Sucrose Alone,&quot; <i>Fetal Diagn Ther</i>, 2009, 25(2):239-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/19506383/pubmed\" target=\"_blank\" id=\"19506383\">19506383</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krishnan R, Shankaran S, Krishnan M, Kauffman RE, Kumar P, Lucena J. Pharmacokinetics of erythropoietin following single-dose subcutaneous administration in preterm infants. <i>Biol Neonate</i>. 1996;70(3):135-140. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/8894079 /pubmed\" target=\"_blank\" id=\"8894079 \">8894079 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maier RF, Obladen M, Scigalla P, et al. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. <i>N Engl J Med</i>. 1994;330(17):1173-1178.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/8139627 /pubmed\" target=\"_blank\" id=\"8139627 \">8139627 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Perry B, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injection in healthy volunteers. <i>Blood</i>. 1990;76(9):1718-1722.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/2224121/pubmed\" target=\"_blank\" id=\"2224121\">2224121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naughton CA, Duppong LM, Forbes KD, et al, &ldquo;Stability of Multidose, Preserved Formulation Epoetin Alfa in Syringes for Three and Six Weeks,&rdquo; <i>Am J Health Syst Pharm</i>, 2003, 60(5):464-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/12635452/pubmed\" target=\"_blank\" id=\"12635452\">12635452</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neubauer AP, Voss W, Wachtendorf M, et al, &quot;Erythropoietin Improves Neurodevelopmental Outcome of Extremely Preterm Infants,&quot; <i>Ann Neurol</i>, 2010, 67(5):657-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/20437563/pubmed\" target=\"_blank\" id=\"20437563\">20437563</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohls RK, Christensen, RD. Stability of human recombinant epoetin alfa in commonly used neonatal intravenous solutions. <i>Ann Pharmacother</i>. 1996;30(5):466-468. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/ 8740324 /pubmed\" target=\"_blank\" id=\" 8740324 \"> 8740324 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohls RK, Harcum J, Schibler KR, Christensen RD. The effect of erythropoietin on the transfusion requirements of preterm infants weighing 750 grams or less: a randomized, double-blind, placebo-controlled study. <i>J Pediatr</i>. 1997;131(5):661-665. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/9403642 /pubmed\" target=\"_blank\" id=\"9403642 \">9403642 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohls RK, Roohi M, Peceny HM, Schrader R, Bierer R. A randomized, masked study of weekly erythropoietin dosing in preterm infants. <i>J Pediatr</i>. 2012;160(5):790-795.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/22137666 /pubmed\" target=\"_blank\" id=\"22137666 \">22137666 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.<i> Database Syst Rev</i>. 2014;4:CD004863.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/24771408 /pubmed\" target=\"_blank\" id=\"24771408 \">24771408 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the american college of physicians. <i>Ann Intern Med</i>. 2013;159(11):770-779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/24297193/pubmed\" target=\"_blank\" id=\"24297193\">24297193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reisenberger K, Egarter C, Kapiotis S, et al, &quot;Transfer of Erythropoietin Across the Placenta Perfused <i>in vitro</i>,&quot; <i>Obstet Gynecol</i>, 1997, 89(5 Pt 1):738-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/9166312/pubmed\" target=\"_blank\" id=\"9166312\">9166312</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Brouwers M, Hurley P, et al, &quot;American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer,&quot; <i>J Clin Oncol</i>, 2010, 28(33):4996-5010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/20975064/pubmed\" target=\"_blank\" id=\"20975064\">20975064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Salmonson T, Danielson BG, and Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. <i>Br J Clin Pharmac</i>. 1990; 29:709-713.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/2378790/pubmed\" target=\"_blank\" id=\"2378790\">2378790</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Semba RD and Juul SE, &quot;Erythropoietin in Human Milk: Physiology and Role in Infant Health,&quot; <i>J Hum Lact</i>, 2002, 18(3):252-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/12192960/pubmed\" target=\"_blank\" id=\"12192960\">12192960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shannon KM, Keith JF 3rd, Mentzer WC, et al, &ldquo;Recombinant Human Erythropoietin Stimulates Erythropoiesis and Reduces Erythrocyte Transfusions in Very Low Birth Weight Preterm Infants,&rdquo; <i>Pediatrics</i>, 1995, 95(1):1-8. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/7770284/pubmed\" target=\"_blank\" id=\"7770284\">7770284</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinai-Trieman L, Salusky IB, and Fine RN, &ldquo;Use of Subcutaneous Recombinant Human Erythropoietin in Children Undergoing Continuous Cycling Peritoneal Dialysis,&rdquo; <i>J Pediatr</i>, 1989, 114(4 Pt 1):550-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/2926567/pubmed\" target=\"_blank\" id=\"2926567\">2926567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wu YW, Bauer LA, Ballard RA, et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. <i>Pediatrics</i>. 2012;130(4):683-691. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/23008465 /pubmed\" target=\"_blank\" id=\"23008465 \">23008465 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhu C, Kang W, Xu F, et al, &quot;Erythropoietin Improved Neurologic Outcomes in Newborns With Hypoxic-Ischemic Encephalopathy,&quot; <i>Pediatrics</i>, 2009, 124(2):e218-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/epoetin-alfa-pediatric-drug-information/abstract-text/19651565/pubmed\" target=\"_blank\" id=\"19651565\">19651565</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13273 Version 140.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708743\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F165764\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F165765\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058391\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442420\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058385\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F165738\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F165724\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874643\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058395\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F165758\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058394\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F165818\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F165814\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F165745\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F165728\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26715203\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299274\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220130\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F165734\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F165749\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058390\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1058393\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F165727\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F165744\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F165748\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F165751\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13273|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=epoetin-alfa-drug-information\" class=\"drug drug_general\">Epoetin alfa: Drug information</a></li><li><a href=\"topic.htm?path=epoetin-alfa-patient-drug-information\" class=\"drug drug_patient\">Epoetin alfa: Patient drug information</a></li></ul></div></div>","javascript":null}